SingWealth Holdings Strengthens Community Resilience Through Health, Wealth and Legacy Conversations at Lianhe Zaobao Event
SINGAPORE, March 23, 2026 /PRNewswire/ -- SingWealth Holdings ('SingWealth') recently stepped forward as the lead sponsor for Lianhe Zaobao's My Legacy and Living Well held on 21 March 2026, reinforcing the Group's commitment to helping Singaporeans navigate critical conversations around health, financial preparedness, and legacy planning. The strong...
Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study
SAN FRANCISCO and SUZHOU, China, March 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the xanthine oxidase inhibitor (XOI) Tigulixostat(R&D code: IBI128) have the first participant dosed in a Phase...
World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target
SHANGHAI, March 22, 2026 /PRNewswire/ -- On the occasion of World Water Day, WuXi Biologics reaffirms its commitment to sustainability through responsible operations and efficient, circular water‑use practices that reduce environmental impact. WuXi Biologics has been named to the CDP Water Security "A List" for three consecutive years, underscoring an industry-leading performance in environmental stewardship and...
Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon...
Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over platinum-containing chemo doublet WU-KONG 28 is the first and only phase 3 study to demonstrate meaningful benefits with an oral, once daily, chemo-free, targeted therapy In addition to improvement in PFS, ZEGFROVY® also...
Quality Protein No Longer a Luxury? Angel Yeast Shows How at FIC 2026
SHANGHAI, March 20, 2026 /PRNewswire/ -- Angel Yeast (SH600298) showcased its latest yeast protein R&D achievements and progress in global applications at FIC 2026 from March 17-19, 2026, reaffirming its commitment to making high-quality protein accessible to everyone. As a key barometer for the food industry, this year's show also highlighted how the...
Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
SHANGHAI, March 20, 2026 /PRNewswire/ -- Henlius (2696.HK) today announced its annual results for the year ended December 31, 2025. During the reporting period, the Company recorded revenue of RMB 6.6666 billion, representing a year-on-year increase of 16.5%, and net profit of RMB 0.8270 billion. Total R&D investment reached RMB 2.4919 billion, an increase of 35.4%. Amid continued investment...
SiiPet Highlights Spring Health Priorities for Cats as Seasonal Initiative Expands Access to AI‑Driven Monitoring
LOS ANGELES, March 20, 2026 /PRNewswire/ -- SiiPet, a growing pet tech startup, announced its Spring Sale initiative, running from March 15 to March 31, marking a renewed effort to make advanced feline health monitoring more widely accessible during a season when many cats experience elevated health risks. SiiPet LitterLens, the world's first health...
Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
WILMINGTON, Del., March 20, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced that it has raised $787 million in financing rounds. The investment included participation by a group of leading global investors, including Dimension Capital, DST Global, INCE Capital, Luminous Ventures, Miracle Capital, Sanofi, and Biotech Development Fund (created by Hillhouse and Pfizer),...
HKSH Cancer Centre’s Precision Targeting Technologies Leading the Evolution of “Hypofractionation”
Asia's First Study: 5 Sessions of Proton Therapy to Control Early-Stage Prostate Cancer HONG KONG, March 20, 2026 /PRNewswire/ -- HKSH Medical Group (HKSH) today announced the results of Asia's first clinical study on early-stage prostate cancer patients receiving five-session of proton therapy.* The results show significant efficacy, with a marked decline in prostate-specific antigen (PSA) levels and only...
Manulife Named “Asia’s Best Insurance Provider for Wealth Management” by Euromoney
HONG KONG, March 20, 2026 /PRNewswire/ -- Manulife today announced it has been named "Asia's Best Insurance Provider for Wealth Management" at the 2026 Euromoney Private Banking Awards. The award recognizes Manulife's excellence in delivering tailored and innovative wealth and legacy planning solutions to High-Net-Worth (HNW) individuals and families across the region. ...
